Cardiovascular Diseases

The Onassis Cardiac Surgery Center advances research in cardiovascular diseases, targeting conditions such as heart failure, hypertrophic cardiomyopathy, and left ventricular systolic dysfunction. Clinical studies test the safety and therapeutic benefit of innovative drugs, including myosin inhibitors and mineralocorticoid receptor antagonists, aiming to enhance cardiac performance and patient well‑being.

  • Hypertrophic cardiomyopathy (obstructive and non‑obstructive)
  • Heart failure with reduced ejection fraction
  • Novel myosin‑modulating agents
  • Mineralocorticoid receptor antagonist therapy
  • Cardiac imaging and functional outcome measures

Long‑term extension phases focus on tolerability, exercise capacity, and imaging biomarkers to confirm durable benefits.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Research at the Cardiology Department includes pediatric investigations of inherited cardiac disorders and early‑life heart failure. Trials evaluate agents such as finerenone in children with left ventricular systolic dysfunction, seeking safe, effective options for young patients with congenital or hereditary cardiomyopathies.

  • Pediatric heart failure and left ventricular dysfunction
  • Genetic cardiomyopathies
  • Safety and dosing of novel therapies in children
  • Impact on growth and developmental outcomes
  • Biomarker‑driven efficacy assessments

The studies emphasize long‑term safety, quality of life, and the potential to expand treatment choices for children with complex cardiac conditions.

Respiratory Tract Diseases

The site’s portfolio also covers respiratory tract diseases, primarily focusing on pulmonary arterial hypertension (PAH) and PAH linked to interstitial lung disease. Clinical programs assess inhaled and injectable therapies—such as ralinepag, seralutinib, sotatercept, and PF‑07868489—to improve hemodynamics, exercise tolerance, and disease progression.

  • Pulmonary arterial hypertension (PAH)
  • PAH associated with interstitial lung disease
  • Inhaled and systemic targeted agents
  • Hemodynamic endpoints (e.g., PVR, 6‑minute walk distance)
  • Patient‑reported outcomes and quality of life

Extended follow‑up studies monitor long‑term tolerability and the durability of clinical benefit in adult participants.